This is in accordance with the molecular testing guideline for the selection of patients with lung cancer for treatment, suggesting that BRAF mutational testing should be performed on all advanced adenocarcinoma patients, irrespective of clinical characteristics [18]. This evidence concerns the gene BRAF and lung carcinoma.